Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS) and INNOVA CAPTAB LIMITED (NSE: INNOVACAP) are both listed in the Domestic contract manufacturers industry. Akums Drugs and Pharmaceuticals has a market capitalisation of ₹11,225 Cr and INNOVA CAPTAB ₹5,729 Cr, as of 9 Nov 2026. Their P/E ratios are 44 and 40.7 respectively. Return on equity is 8.02% for Akums Drugs and Pharmaceuticals and 14.03% for INNOVA CAPTAB. Over one year, Akums Drugs and Pharmaceuticals's share price is up 66.0% and INNOVA CAPTAB's is up 31.7%.
| Metric | Akums Drugs and Pharmaceuticals | INNOVA CAPTAB |
|---|---|---|
| NSE Symbol | AKUMS | INNOVACAP |
| BSE Code | 544222 | 544067 |
| Share Price | ₹765.00 | ₹1,070.00 |
| Market Cap | ₹11,225 Cr | ₹5,729 Cr |
| P/E Ratio | 44 | 40.7 |
| Return on Equity | 8.02% | 14.03% |
| Return on Assets | 4.84% | 6.83% |
| Dividend Yield | 0.14% | 0.40% |
| Beta (1Y) | 0.33 | 0.54 |
| 1-Year Price Change | +66.0% | +31.7% |
| 3-Month Price Change | +4.8% | +10.8% |
| 52-Week Range | ₹409.30 – ₹838.80 | ₹622.00 – ₹1,353.50 |
| Latest Quarter | Q2 FY27 | Q1 FY27 |
| Quarterly Revenue | ₹1,342 Cr | ₹471 Cr |
| Quarterly Net Profit | ₹115 Cr | ₹44 Cr |
| Net Margin | 8.5% | 9.4% |
| EPS (Basic, Quarter) | ₹7.37 | ₹7.71 |
| Results Basis | consolidated | consolidated |
| Headquarters | Delhi | Panchkula, Haryana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry…
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, a…
Akums Drugs and Pharmaceuticals has a market capitalisation of ₹11,225 Cr, against ₹5,729 Cr for INNOVA CAPTAB as of 9 Nov 2026, about 2.0 times the size by market cap.
Akums Drugs and Pharmaceuticals has a P/E of 44 and INNOVA CAPTAB a P/E of 40.7 as of 9 Nov 2026.
Akums Drugs and Pharmaceuticals has a return on equity of 8.02% and INNOVA CAPTAB 14.03%.
Akums Drugs and Pharmaceuticals's share price is up 66.0% over one year and INNOVA CAPTAB's is up 31.7%.
Akums Drugs and Pharmaceuticals reported revenue of ₹1,342 Cr and net profit of ₹115 Cr for Q2 FY27. INNOVA CAPTAB reported revenue of ₹471 Cr and net profit of ₹44 Cr for Q1 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Domestic contract manufacturers on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.